Henry Skinner, PhD, MBE, MJur

About

As a microbiologist, venture investor, and executive, Henry Skinner, PhD, MBE, MJur, has spent his career working to overcome the scientific and economic challenges associated with antimicrobial drug development. His cross-disciplinary expertise has been essential to shaping the AMR Action Fund’s investment portfolio and policy priorities, with an emphasis on issues pertaining to R&D, innovative financing, and equitable access. Dr. Skinner is regularly sought out for high-level speaking engagements to discuss the global threat of AMR and is frequently featured in the media, including The New York Times, The Wall Street Journal, Bloomberg News, and the Financial Times.

Source (opens in a new tab)